Rexahn Pharmaceuticals to Participate in Brean Capital 2013 Life Sciences Summit
ROCKVILLE, Md.--(BUSINESS WIRE)--Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today...
View ArticleRexahn Pharmaceuticals Reports Third Quarter Financial Results and Pipeline...
ROCKVILLE, Md.--(BUSINESS WIRE)--Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN) a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer is providing a...
View ArticleRexahn Pharmaceuticals Announces Publication of Preclinical Data for Novel...
ROCKVILLE, Md.--(BUSINESS WIRE)--Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN), a clinical stage biopharmaceutical company developing potential best-in-class oncology therapies, today announced the...
View ArticleRexahn Pharmaceuticals to Present at the 15th Annual Rodman & Renshaw Global...
(Source: Rexahn Pharmaceuticals Inc) Rockville, MD, September 5, 2013 - Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN) a clinical stage biopharmaceutical company developing best-in-class therapeutics for...
View ArticleRexahn Pharmaceuticals Announces Teva will not Exercise its Option to License...
Rexahn Retains its Rights to Cancer Treatment Compound RX-3117 ROCKVILLE, Md.--(BUSINESS WIRE)-- Rexahn Pharmaceuticals (RNN) announced today that Teva Pharmaceutical Industries has decided, for...
View ArticleRexahn Pharmaceuticals Provides a Clinical Development and Financial Update
Fortified balance sheet to fund initiation of three clinical trials in 2013 with data expected in 2014 ROCKVILLE, Md.--(BUSINESS WIRE)-- Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN) a clinical stage...
View ArticleRexahn Awarded Patent in Europe for Cancer Drug Archexin®
ROCKVILLE, Md.--(BUSINESS WIRE)--Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today...
View ArticleRexahn Pharmaceuticals Initiates Dosing in Phase I Trial of SupinoxinTM...
Oral inhibitor of phosphorylated-p68 RNA helicase marks Rexahns third oncology compound in clinical development ROCKVILLE, Md.--(BUSINESS WIRE)-- Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN) a clinical...
View ArticleRexahn Pharmaceuticals Provides a Clinical Development and Financial Update...
(Source: Rexahn Pharmaceuticals Inc) Rexahn Pharmaceuticals Provides a Clinical Development and Financial Update Fortified balance sheet to fund initiation of three clinical trials in 2013 with data...
View ArticleRexahn Pharmaceuticals Announces Teva will not Exercise its Option to License...
(Source: Rexahn Pharmaceuticals Inc) Rexahn Retains its Rights to Cancer Treatment Compound RX-3117 Rockville, Maryland, August 28, 2013 - Rexahn Pharmaceuticals (NYSE MKT: RNN) announced today that...
View ArticleRexahn Pharmaceuticals In-Licenses Novel Oligonucleotide Targeted Drug...
Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN), a clinical stage biopharmaceutical company, announced today that it has signed an exclusive license agreement with the Ohio State Innovation Foundation, an...
View ArticleRexahn Pharmaceuticals In-Licenses Novel Oligonucleotide Targeted Drug...
ROCKVILLE, Md.--(BUSINESS WIRE)--Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN), a clinical stage biopharmaceutical company, announced today that it has signed an exclusive license agreement with the...
View ArticleRexahn Pharmaceuticals In-Licenses Novel Oligonucleotide Targeted Drug...
(Source: Rexahn Pharmaceuticals Inc) Lipid-Coated Albumin Nanoparticle (LCAN) platform improves safety and maximizes efficacy of oligonucleotide molecules Rockville, MD, October 10, 2013 - Rexahn...
View ArticleRexahn Pharmaceuticals In-Licenses Breakthrough Oncology Drug Delivery Platform
Maximizes efficacy and minimizes toxicity of currently marketed anti-cancer drugs RX-21101 identified as first development candidate from platform ROCKVILLE, Md.--(BUSINESS WIRE)-- Rexahn...
View ArticleRexahn Pharmaceuticals In-Licenses Breakthrough Oncology Drug Delivery...
(Source: Rexahn Pharmaceuticals Inc) Maximizes efficacy and minimizes toxicity of currently marketed anti-cancer drugs RX-21101 identified as first development candidate from platform Rockville, MD,...
View ArticleRexahn Receives Method Patent for Treatment of Solid Tumor Cancers for...
ROCKVILLE, Md.--(BUSINESS WIRE)--Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN), a clinical stage biopharmaceutical company developing potential best-in-class oncology therapies, today announced that it...
View ArticleRexahn Pharmaceuticals to Present at the 16th Annual BIO CEO & Investor...
ROCKVILLE, Md.--(BUSINESS WIRE)--Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN) a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today...
View ArticleRexahn Pharmaceuticals to Present at the 26th Annual ROTH Conference
ROCKVILLE, Md.--(BUSINESS WIRE)--Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today...
View ArticleRexahn Pharmaceuticals Reports Fourth Quarter and Full-Year 2013 Financial...
ROCKVILLE, Md.--(BUSINESS WIRE)--Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN) a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, is providing...
View ArticleRexahn Pharmaceuticals Reports Fourth Quarter and Full-Year 2013 Financial...
(Source: Rexahn Pharmaceuticals Inc) Supinoxin™ Phase I clinical trial enters fourth dosing group; preliminary data announced in March 2014 Archexin® Phase IIa clinical trial initiated in metastatic...
View ArticleRexahn Pharmaceuticals to Present Data on RX-3117 and RX-21101 at the 2014...
ROCKVILLE, Md.--(BUSINESS WIRE)--Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN) a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today...
View ArticleRexahn Pharmaceuticals to Present Data on RX-3117 and RX-21101 at the 2014...
(Source: Rexahn Pharmaceuticals Inc) RX-3117 is effective in gemcitabine resistant human cancer cell lines RX-21101,a nano-polymer targeted form of docetaxel, demonstrates increased efficacy and...
View ArticleRexahn Presents Data from Preclinical Studies of RX-21101
ROCKVILLE, Md.--(BUSINESS WIRE)--Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN) a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today...
View ArticleRexahn Presents Data from Preclinical Studies of RX-21101 (Rexahn...
(Source: Rexahn Pharmaceuticals Inc) Proprietary nano-polymer conjugate of docetaxel shows increased efficacy and reduced toxicity for this widely used FDA-approved chemo drug ROCKVILLE, Md.--(BUSINESS...
View ArticleRexahn Announces Additional Data from Preclinical Studies of RX-3117
ROCKVILLE, Md.--(BUSINESS WIRE)--Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN) a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today...
View ArticleRexahn Announces Additional Data from Preclinical Studies of RX-3117 (Rexahn...
(Source: Rexahn Pharmaceuticals Inc) Potent efficacy in animal models with tumors resistant to gemcitabine, a widely used chemotherapy drug ROCKVILLE, Md.--(BUSINESS WIRE)-- Rexahn Pharmaceuticals,...
View ArticleRexahn Pharmaceuticals Reports First Quarter 2014 Financial Results and...
ROCKVILLE, Md.--(BUSINESS WIRE)--Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, is providing...
View ArticleRexahn Pharmaceuticals Reports First Quarter 2014 Financial Results and...
(Source: Rexahn Pharmaceuticals Inc) Three clinical trials ongoing with key milestones expected in Q4 2014 ROCKVILLE, Md.--(BUSINESS WIRE)-- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical...
View ArticleRexahn Pharmaceuticals Provides Update on Phase I Supinoxin Trial in Cancer...
Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today announced an update in its Phase I...
View ArticleRexahn Pharmaceuticals Provides Update on Phase I Supinoxin Trial in Cancer...
(Source: Rexahn Pharmaceuticals Inc) Patient enrollment on schedule for completion in Q4 2014 ROCKVILLE, Md.--(BUSINESS WIRE)-- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage...
View ArticleRexahn Pharmaceuticals Reports Second Quarter 2014 Financial Results and...
ROCKVILLE, Md.--(BUSINESS WIRE)--Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, is providing...
View ArticleRexahn Pharmaceuticals Reports Second Quarter 2014 Financial Results and...
(Source: Rexahn Pharmaceuticals Inc) Continued Progress in the RX-3117, Supinoxin and Archexin Clinical Development Programs ROCKVILLE, Md.--(BUSINESS WIRE)-- Rexahn Pharmaceuticals, Inc. (NYSE MKT:...
View ArticleRexahn Receives a Notice of Allowance from the U.S. Patent and Trademark...
ROCKVILLE, Md.--(BUSINESS WIRE)--Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today...
View ArticleRexahn Receives a Notice of Allowance from the U.S. Patent and Trademark...
(Source: Rexahn Pharmaceuticals Inc) Company expands its pipeline of breakthrough drug delivery technologies designed to improve the efficacy and safety of widely used FDA-approved anti-cancer drugs...
View ArticleRexahn Receives FDA Orphan Drug Designation for RX-3117 in Treatment of...
(Source: Rexahn Pharmaceuticals Inc) ROCKVILLE, Md., Sept. 24, 2014 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing best-in-class...
View ArticleRexahn Pharmaceuticals Reports Third Quarter 2014 Financial Results and...
(Source: Rexahn Pharmaceuticals Inc) ROCKVILLE, Md., Nov. 13, 2014 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing best-in-class...
View ArticleRexahn Pharmaceuticals Announces Publication of Preclinical Data for RX-3117...
(Source: Rexahn Pharmaceuticals Inc) ROCKVILLE, Md., Jan. 6, 2015 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing best-in-class...
View ArticleRexahn Pharmaceuticals to Present at the 17th Annual BIO CEO & Investor...
ROCKVILLE, Md., Feb. 2, 2015 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN) a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of...
View ArticleRexahn Pharmaceuticals to Present at the ROTH Capital Partners 27th Annual...
ROCKVILLE, Md., March 2, 2015 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN) a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of...
View ArticleNational Cancer Institute Accepts Rexahn's RX-21101 for Its Nanotechnology...
Program Will Provide Foundation for Filing an IND Application for Phase I Trial ROCKVILLE, Md., June 8, 2015 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE:RNN), a clinical stage...
View ArticleRexahn Pharmaceuticals Awarded Patent in Japan for Novel Targeted Cancer Drug...
(Source: Rexahn Pharmaceuticals Inc) July 14, 2015 Rexahn Pharmaceuticals Awarded Patent in Japan for Novel Targeted Cancer Drug Deliver Platform ROCKVILLE, Md., July 14, 2015 (GLOBE NEWSWIRE) --...
View ArticleRexahn Pharmaceuticals Awarded Patent in Japan for Novel Targeted Cancer Drug...
(Source: Rexahn Pharmaceuticals Inc) ROCKVILLE, Md., July 14, 2015 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing best-in-class...
View ArticleRexahn Pharmaceuticals Reports Second Quarter 2015 Financial Results and...
(Source: Rexahn Pharmaceuticals Inc) August 10, 2015 Rexahn Pharmaceuticals Reports Second Quarter 2015 Financial Results and Provides Corporate Update Presentations at Recent Scientific Conferences...
View ArticleRexahn Pharmaceuticals Reports Second Quarter 2015 Financial Results and...
Presentations at Recent Scientific Conferences Showcase Novel Anti-Tumor Properties of Rexahn Compounds ROCKVILLE, Md., Aug. 10, 2015 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a...
View ArticleRexahn Pharmaceuticals Reports Third Quarter 2014 Financial Results and...
Encouraging Data From Dose-Escalation Studies, Plus FDA Orphan Drug Designation in Pancreatic Cancer ROCKVILLE, Md., Nov. 13, 2014 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a...
View Article
